‘Supect’ to become a primary treatment in leukemia
‘Supect,’ which has shown the power of domestic product in the flood of multinational pharmaceutical companies’ products, has overcome the obstacle of the secondary treatment. Having inexpensive price and proving excellent effectiveness, the drug has been approved as a primary treatment.
When it...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
